Needham Lifts PT on Neumora Therapeutics (NMRA) to $8 From $6, Keeps a Buy Rating
Neumora Therapeutics, Inc. (NASDAQ:NMRA) has recently gained attention as one of the best stocks under $5 with the highest upside potential. Needham, a reputable financial firm, raised its price target on Neumora Therapeutics to $8 from $6 while maintaining a Buy rating on the stock. The firm expressed increased optimism following the company’s R&D Investor Event, where its broad pipeline was showcased.
Similarly, Guggenheim upgraded Neumora Therapeutics to Buy from Neutral on October 27, setting a price target of $14 on the shares. This upgrade came after the company reported compelling preclinical obesity data, prompting Guggenheim to believe that Neumora’s NLRP3i program in obesity and related disorders could drive significant value creation.
Neumora Therapeutics, Inc. is a clinical-stage biotechnology company that specializes in integrating neuroscience and data science to provide a precision medicine approach for brain diseases. The company’s primary focus is on developing medicines for therapeutically relevant targets associated with CNS diseases.
While Neumora Therapeutics shows promise as an investment opportunity, some AI stocks may offer greater upside potential with less downside risk. For investors seeking an undervalued AI stock poised to benefit from Trump-era tariffs and the onshoring trend, a free report on the best short-term AI stock is available.
For more insights into potential investment opportunities, check out “30 Stocks That Should Double in 3 Years” and “11 Hidden AI Stocks to Buy Right Now.”
Disclosure: None. This article was originally published on Insider Monkey.
